James Dillard - Perrigo Company Executive Vice President Chief Scientific Officer

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:3em;padding-top: 25px;;'>PRG</div>
PRGO -- USA Stock  

Last Earning Anouncement Date: December 31, 2015  

Mr. James E. Dillard is an Executive Vice President and Chief Scientific Officer at Perrigo Company Public Limited Company. Mr. Dillard joined Perrigo from Altria Group, Inc., where he served as Senior Vice President, Research, Development and Sciences and Chief Innovation Officer from January 2009 to May 2018. During his tenure with Altria Group, Mr. Dillard led the creation of the Regulatory Affairs function in 2009 and also served as Chief Innovation Officer for Altria Client Services and Senior Vice President of Research, Development Regulatory Affairs for Altria Group. He held science and technology leadership roles with U.S. Smokeless Tobacco Company, an Altria Group Inc. operating company, from 2001 to 2009. Mr. Dillard worked for the U.S. Food and Drug Administration between 1987 and 2001 as Director of the Division of Cardiovascular and Respiratory Devices, as well as in various leadership roles in the Center for Devices and Radiological Health and the Office of Device Evaluation.
Age: 54  President Since 2019      
353 1 709 4000  http://www.perrigo.com

James Dillard Latest Insider Activity

James Dillard over two months ago via Macroaxis 
Sale by James Dillard of 26647 shares of Altria

Management Efficiency

The company has return on total asset (ROA) of 2.19 % which means that it generated profit of $2.19 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 4.32 % meaning that it created $4.32 on every $100 dollars invested by stockholders.
The company currently holds 3.5 B in liabilities with Debt to Equity (D/E) ratio of 60.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Perrigo Company has Current Ratio of 2.03 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Raghav ChariDr Reddys Laboratories Ltd
John GrayVertex Pharmaceuticals Incorpor
Glenn DavidZoetis
Christopher FenimoreRegeneron Pharmaceuticals
Cartikeya ReddyDr Reddys Laboratories Ltd
Catherine KnuppZoetis
Thomas GraneyVertex Pharmaceuticals Incorpor
Michael PartridgeVertex Pharmaceuticals Incorpor
Kimberly WhiteVertex Pharmaceuticals Incorpor
Alok SonigDr Reddys Laboratories Ltd
Charles MilsteinVertex Pharmaceuticals Incorpor
Sandra BeatyZoetis
Alejandro BernalZoetis
Peter PowchikRegeneron Pharmaceuticals
Samiran DasDr Reddys Laboratories Ltd
George YancopoulosRegeneron Pharmaceuticals
Michael PariniVertex Pharmaceuticals Incorpor
K RaoDr Reddys Laboratories Ltd
Paul SilvaVertex Pharmaceuticals Incorpor
Roxanne LaganoZoetis
Amit BiswasDr Reddys Laboratories Ltd

Entity Summary

Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland. Perrigo Company operates under Drug ManufacturersSpecialty Generic classification in USA and is traded on BATS Exchange. It employs 10600 people.Perrigo Company Plc (PRGO) is traded on BATS Exchange in USA and employs 10,600 people.

Perrigo Company Leadership Team

John Hendrickson, President
Gary Cohen, Independent Director
Arthur Shannon, IR Contact Officer
Ronald Winowiecki, Acting CFO
Svend Andersen, Executive Vice President and President - Consumer Healthcare International
Judy Brown, CFO and Executive VP
Laurie Brlas, Independent Director
Donal OConnor, Independent Director
James Michaud, Chief Human Resource Officer, Executive Vice President
Louis Yu, Executive Vice President - Global Quality
John Wesolowski, Executive Vice President and Presidentident - RX
Theodore Samuelsto, Independent Director
Scott Jamison, Executive Vice President General Manager - Nutritionals
Ellen Hoffing, Independent Director
Marc Coucke, Executive Vice President General Manager - Omega Pharma Business
Adriana Karaboutis, Independent Director
Michael Jandernoa, Independent Director
Paul Weninger, Executive Vice President - Global Quality Operations
Thomas Farrington, Senior Vice President CIO
Herman Morris, Independent Director
Jeffrey Needham, Executive Vice President General Manager - Consumer Healthcare
Todd Kingma, Executive VP, General Counsel and Secretary
Rolf Classon, Independent Director
Raymond Silcock, CFO
Shlomo Yanai, Independent Director Nominee
Jatin Shah, Senior Vice President Chief Scientific Officer
Michael Stewart, Senior Vice President - Global Human Resources
Jeffrey Kindler, Independent Director
Jacqualyn Fouse, Independent Director
Grainne Quinn, Executive Vice President Chief Medical Officer
Theodore Samuels, Independent Director
Geoffrey Parker, Independent Director
Murray Kessler, President CEO, Director
Sharon Kochan, Executive VP and General Manager of International
Gary Kunkle, Lead Independent Director
Joseph Papa, Chairman and CEO
Marry Brlas, Independent Chairman of the Board
Bradley Alford, Independent Director
Jeffrey Smith, Independent Director
Bradley Joseph, IR Contact Officer
James Dillard, Executive Vice President Chief Scientific Officer
Douglas Boothe, Executive Vice President General Manager - Rx Pharmaceuticals
Ronald Janish, Executive Vice President - Global Operations and Supply Chain
Uwe Rohrhoff, President CEO, Director

Stock Performance Indicators

Did you try this?

Run Idea Optimizer Now


Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
All  Next Launch Module

Currently Active Assets on Macroaxis

Purchased few shares of
few hours ago
Traded for 55.68
Purchased few shares of
few hours ago
Traded for 85.37
Purchased one share of
few hours ago
Traded for 209.15
Purchased one share of
few hours ago
Traded for 333.5
Purchased few shares of
few hours ago
Traded for 59.01
Please also check Your Equity Center. Please also try Portfolio Manager module to state of the art portfolio manager to monitor and improve performance of your invested capital.